LEXX vs CYBN

Analysts rate Cybin Inc.

(CYBN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Lexaria Bioscience Corp.

(LEXX) delivered a total return of -89. 8%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: LEXX returned -85. 7% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lexaria Bioscience Corp.

(LEXX) is the lower-risk stock at 1. 00β versus Cybin Inc. 's 1. 52β — meaning CYBN is approximately 52% more volatile than LEXX relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Cybin Inc.

grew EPS 93. 5% year-over-year, compared to -40. 4% for Lexaria Bioscience Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cybin Inc.

(CYBN) is the more profitable company, earning 0. 0% net margin versus -1686. 0% for Lexaria Bioscience Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CYBN leads at 0. 0% versus -1648. 0% for LEXX. At the gross margin level — before operating expenses — LEXX leads at 83. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lexaria Bioscience Corp.

(LEXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00)). Cybin Inc. (CYBN) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEXX: -85. 7%, CYBN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LEXX is a small-cap high-growth stock; CYBN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.